Japan approved an antiviral pill from Shionogi to treat Covid-19 after the company provided new data to show the drug's efficacy
TOKYO—Japan approved an antiviral pill from Shionogi & Co. to treat Covid-19 after the company provided new data to show the drug’s efficacy.
The treatment is the first locally developed alternative to Pfizer Inc.’s Paxlovid and Merck & Co.’s Lagevrio, which in Japan. Shionogi aims to win approval from the Food and Drug Administration for its pill in the U.S.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Japan's Shionogi shares jump after report of COVID drug gaining efficacy approvalShares in Japanese drugmaker Shionogi & Co Ltd rose nearly 3% by mid-morning on Tuesday after the Yomiuri newspaper said the country's regulatory agency had compiled a report confirming the possible efficacy of the company's COVID-19 drug.
Lire la suite »
From COVID tongue to COVID toes, the disease may cause weird symptomsFrom head to COVID toe, doctors have seen a bevy of bizarre cases.
Lire la suite »
Japan to grant emergency approval to Shinogi COVID-19 drugJapan on Friday said it would grant emergency approval to Japanese drugmaker Shionogi & Co Ltd's COVID-19 drug, making it the first domestically developed oral drug for patients with mild symptoms.
Lire la suite »
Children's Discovery Museum Offers Free COVID-19 Shots, Free Admission at Sunday Vaccine ClinicFamilies whose children or adults get vaccinated at San Jose’s Children Discovery Museum on Sunday can receive free admission for the museum, too.
Lire la suite »
Hidden COVID crisis: Violent juvenile crime exploded amid school shutdowns“We are seeing, and I hear this from chiefs and sheriffs all the time, as well as our own agents, an alarming uptick in the incidence of juveniles engaging in violence, often graduating from carjackings to even worse violence,” FBI Director Christopher Wray said.
Lire la suite »